bluebird bio
JOBS
IN THE PRESS
bluebird and Celgene will share 50% of U.S. costs and profits
bluebird bio, Inc. today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2017.
In this role, Alison will be responsible for shaping and delivering an integrated global commercial strategy to make bluebird’s gene therapies broadly accessible to patients.
bluebird bio today announced that it has issued an additional 277,109 shares of common stock at the public offering price of $185 per share, for total gross proceeds of approximately $51.3 million.
Goldman Sachs 10th Annual Healthcare CEOs Unscripted, Thursday, January 4, at 3:15 p.m. ET at the InterContinental, Boston, Massachusetts.
MilliporeSigma today announced that it has signed a commercial supply agreement to manufacture viral vectors for bluebird bio for its use in potentially transformative gene therapies.
bluebird bio announced the pricing of an underwritten public offering of 3,243,244 shares of its common stock at a public offering price of $185 per share, before underwriting discounts.
bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering.
These data will be presented by Marina Cavazzana, M.D., Ph.D., Professor of Medicine at Paris Descartes University and Research Director at the Centre for Clinical Research in Biotherapy,
bluebird bio announced that updated clinical results from HGB-206, the company’s ongoing Phase 1 multicenter study of its LentiGlobin gene therapy product candidate in patients with severe sickle cell disease (SCD), will be discussed in an oral presentation during the 59th Annual Meeting of the American Society of Hematology (ASH).